Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C

M Simin; J Brok; D Stimac; C Gluud; L L Gluud

doi:10.1111/j.1365-2036.2007.03294.x

Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C

M Simin
, J Brok
, D Stimac
, C Gluud
, L L Gluud

Region Hovedstaden

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Abstract

About 170 million patients worldwide have chronic hepatitis C. Pegylated interferon plus ribavirin is currently the recommended therapy.

Originalsprog	Engelsk
Tidsskrift	Alimentary Pharmacology & Therapeutics
Vol/bind	25
Udgave nummer	10
Sider (fra-til)	1153-62
Antal sider	10
ISSN	0269-2813
DOI	https://doi.org/10.1111/j.1365-2036.2007.03294.x
Status	Udgivet - 15. maj 2007
Udgivet eksternt	Ja

Dokumenter og links

10.1111/j.1365-2036.2007.03294.x

SDU link

Tjek adgangen til materialet i Syddansk Universitetsbiblioteks søgemaskine

Citationsformater

@article{59b4586c7c5b4eccb67c1fa29c894bcd,

title = "Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C",

abstract = "About 170 million patients worldwide have chronic hepatitis C. Pegylated interferon plus ribavirin is currently the recommended therapy.",

author = "M Simin and J Brok and D Stimac and C Gluud and Gluud, \{L L\}",

year = "2007",

month = may,

day = "15",

doi = "10.1111/j.1365-2036.2007.03294.x",

language = "English",

volume = "25",

pages = "1153--62",

journal = "Alimentary Pharmacology \& Therapeutics",

issn = "0269-2813",

publisher = "Wiley",

number = "10",

}

TY - JOUR

T1 - Cochrane systematic review

T2 - pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C

AU - Simin, M

AU - Brok, J

AU - Stimac, D

AU - Gluud, C

AU - Gluud, L L

PY - 2007/5/15

Y1 - 2007/5/15

N2 - About 170 million patients worldwide have chronic hepatitis C. Pegylated interferon plus ribavirin is currently the recommended therapy.

AB - About 170 million patients worldwide have chronic hepatitis C. Pegylated interferon plus ribavirin is currently the recommended therapy.

U2 - 10.1111/j.1365-2036.2007.03294.x

DO - 10.1111/j.1365-2036.2007.03294.x

M3 - Journal article

C2 - 17451561

SN - 0269-2813

VL - 25

SP - 1153

EP - 1162

JO - Alimentary Pharmacology & Therapeutics

JF - Alimentary Pharmacology & Therapeutics

IS - 10

ER -

Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C

Abstract

Dokumenter og links

SDU link

Fingeraftryk

Citationsformater